Definitive Healthcare Corp. Class A ((DH)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Definitive Healthcare’s latest earnings call painted a cautious but hopeful picture for investors. Management acknowledged sustained revenue pressure, particularly from life sciences clients and shorter contract terms, yet highlighted expanding margins, robust cash flow, and tangible progress in product quality and innovation, arguing these foundations can support a return to growth over time.
Revenue Holds High End of Guidance Despite Decline
Definitive Healthcare reported Q1 revenue of $55.9 million, landing at the high end of its guidance even as sales fell 6% year over year. Management framed the quarter as evidence that, despite demand headwinds, the company can still execute within its targets and maintain confidence in full‑year revenue and profit goals.
Margins Expand on Strong Profitability
Profitability was a bright spot, with adjusted EBITDA reaching $15.3 million and a 27% margin, expanding about 260 basis points from last year. Adjusted gross profit came in at $45.2 million and gross margin rose to 81%, up roughly 150 basis points, underscoring tighter cost control and improved efficiency even as revenue declines.
Cash Generation Supports Strategic Flexibility
The company emphasized its cash engine, pointing to roughly $50 million of unlevered free cash flow over the past 12 months and $18 million generated in Q1 alone. Trailing‑12‑month operating cash flow of $39.3 million gives management room to invest in product, data, and AI initiatives without stretching the balance sheet.
Professional Services Delivers Double‑Digit Growth
Professional services remained a growth driver, with revenue up 25% year over year as clients leaned on analytics projects and emerging digital activation work. Management suggested this high‑touch activity not only boosts services revenue but also deepens relationships that could support future subscription and data upsell opportunities.
Retention Gains and Customer Win‑backs Accelerate
Customer dynamics showed signs of healing, as net dollar retention improved on a trailing 12‑month basis and the company logged its strongest win‑back quarter in more than three years. Several six‑figure deals returned, with around 160 customers won back last year and more than 50 in Q1 alone, giving management confidence that product and service changes are resonating.
Faster Integrations Enhance Customer Experience
Integration efficiency improved sharply, with nearly 50 new integrations completed in Q1 and a 75% increase over the last six months versus the prior period. Average integration time dropped from more than 100 days to roughly 45 days, aided by a new HubSpot integration and enhanced Salesforce connections designed to embed data more deeply into client workflows.
Claims Remediation Restores Data Quality
Management highlighted that the fall expansion pack and added data sources have materially upgraded claims coverage and quality. They now see claims data back at or above historical levels, easing a significant headwind that previously weighed on customer satisfaction and contributed to weakness in certain segments.
AI and Product Innovation Take Center Stage
Definitive Healthcare is leaning into AI‑enabled offerings, with its first AI‑powered solutions expected later this quarter. Capitalized software development reached nearly $3 million in Q1, up more than $1.5 million year over year, as the company aims to democratize insights for users and ultimately strengthen retention and pricing power.
Digital Activation Gains Momentum
Digital activation continued to gain traction, with more than 30 agencies signed and over half now actively generating bookings, up from roughly one‑third last quarter. Management cited a benchmark showing its audiences delivered a 63% higher click‑through rate than a leading competitor, positioning the product as a differentiated marketing channel.
Top‑Line Headwinds and Guidance Reflect Ongoing Pressure
Despite operational gains, top‑line pressure remains evident as Q1 revenue fell 6% year over year and Q2 guidance of $55–56 million implies an 8–9% decline. Full‑year 2026 revenue guidance of $220–226 million points to a 6–9% drop, underscoring that the turnaround in demand and contract expansion is expected to be gradual rather than immediate.
Life Sciences Segment Continues to Lag
The life sciences business remains a weak spot, with customers slower to ramp spending and more sensitive to past claims disruptions. Management noted muted demand for second‑stage commercialization work and acknowledged that this segment is disproportionately driving the revenue decline, even as other parts of the portfolio stabilize.
Deferred Revenue and RPO Signal Softer Demand
Leading indicators also softened, with deferred revenue at $99 million, down 12% year over year, and total remaining performance obligations off 18%. Current RPO fell 12% to $161 million, reflecting not only weaker bookings but also a structural shift toward shorter‑term agreements that reduce visible future revenue.
Goodwill Impairment and Accounting Noise
The company recorded a non‑cash $197 million goodwill impairment as of March 31, triggered by the decline in its stock price, though it was excluded from adjusted earnings metrics. Related remeasurement items included a roughly $6.6 million gain on a tax receivable agreement liability and a $3.6 million deferred tax benefit, adding some accounting noise but limited economic impact.
Cash Conversion Slows from Prior Peaks
While cash levels remain solid, the conversion of trailing 12‑month adjusted EBITDA to unlevered free cash flow slipped to about 70%, down around 20 percentage points year over year. Management attributed the drop to unique items in the prior period, but the lower conversion underscores that near‑term cash efficiency is not as elevated as last year’s peak.
Shift to Shorter Contracts Weighs on Backlog
A pronounced move toward single‑year contracts over multiyear deals pressured contracted and remaining performance obligations, with management citing about a $15 million headwind for current RPO. They cautioned that this dynamic will likely keep CRPO under pressure for several quarters until comparisons ease, even if underlying demand stabilizes.
Forward‑Looking Guidance and Outlook
For Q2 2026, the company guided revenue to $55–56 million with adjusted EBITDA of $13–14.5 million and margins of 24–26%, while expecting continued double‑digit growth in professional services. For the full year, management reaffirmed revenue of $220–226 million and raised the midpoint of adjusted EBITDA guidance to $57 million, signaling confidence that margin expansion, AI investments, and operational improvements can offset revenue softness.
Definitive Healthcare’s earnings call balanced realism about ongoing revenue declines and life sciences weakness with optimism around margin gains, cash generation, and product progress. For investors, the story hinges on whether improved retention, faster integrations, stronger data, and new AI‑enabled offerings can eventually reignite top‑line growth and validate management’s constructive, if patient, outlook.